Exploration of 3-aminoazetidines as triple reuptake inhibitors by bioisosteric modification of 3-α-Oxyazetidine

ACS Medicinal Chemistry Letters

Volumn 5, Issue 9, 2014, Pages 999-1004

  Han, Minsoo ^a,b   Song, Chiman ^a   Jeong, Nakcheol ^b   Hahn, Hoh Gyu ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

Author keywords

3 aminoazetidines; bioisosterism; Depression; triple reuptake inhibitor

Indexed keywords

3 ALPHA OXYAZETIDINE DERIVATIVE; 3 AMINOAZETIDINE DERIVATIVE; ANTIDEPRESSANT AGENT; AZETIDINE DERIVATIVE; DOPAMINE; DULOXETINE; FLUOXETINE; MIBEFRADIL; NISOXETINE; NORADRENALIN; SEROTONIN; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; VANOXERINE; VENLAFAXINE;

AMES TEST; ANTIDEPRESSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOISOSTERISM; BLOOD BRAIN BARRIER; DEPRESSION; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN CELL; IC50; ISOMERISM; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84907506775     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500187a     Document Type: Article

References (26)

1. Millan, M. J. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs Neurotherapeutics 2009, 6, 53-77
2. Kulkarni, S. K.; Dhir, A. Current investigational drugs for major depression Expert Opin. Invest. Drugs 2009, 18, 767-788
3. Skolnick, P.; Basile, A. S. Triple reuptake inhibitors as antidepressants Drug Discovery Today: Ther. Strategies 2006, 3, 489-494
4. Holtzheimer, P. E., III; Nemeroff, C. B. Advances in the treatment of depression Neurotherapeutics 2006, 3, 42-56
5. Zisook, S.; Rush, A. J.; Haight, B. R.; Clines, D. C.; Rockett, C. B. Use of bupropion in combination with serotonin reuptake inhibitors Biol. Psychiatry 2006, 59, 203-210
6. Papakostas, G. I.; Worthington, J. J.; Iosifescu, I. I. I.; Kinrys, D. V.; Burns, G.; Fisher, A. M.; Homberger, L. B.; Mischoulon, C. H.; Fava, D. M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder Depression Anxiety 2006, 23, 178-181
7. Artigas, F. Future Directions for Serotonin and Antidepressants ACS Chem. Neurosci. 2013, 4, 5-8
8. Prins, J.; Olivier, B.; Korte, S. M. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited Expert Opin. Invest. Drugs 2011, 20, 1107-1130
9. Micheli, F.; Cavanni, P.; Andreotti, D.; Arban, R.; Benedetti, R.; Bertani, B.; Bettati, M.; Bettelini, L.; Bonanomi, G.; Braggio, S.; Carletti, R.; Checchia, A.; Corsi, M.; Fazzolari, E.; Fontana, S.; Marchioro, C.; Merlo-Pich, E.; Negri, M.; Oliosi, B.; Ratti, E.; Read, K. D.; Roscic, M.; Sartori, I.; Spada, S.; Tedesco, G.; Tarsi, L.; Terreni, S.; Visentini, F.; Zocchi, A.; Zonzini, L.; Fabio, R. D. 6-(3,4-Dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A new potent and selective triple reuptake inhibitor J. Med. Chem. 2010, 53, 4989-5001
10. Dunlop, B. W.; Nemeroff, C. B. The role of dopamine in the pathophysiology of depression Arch. Gen. Psychiatry 2007, 64, 327-337
11. Prica, C.; Hascoet, M.; Bourin, M. Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? Behav. Brain. Res. 2008, 194, 92-99
12. Hull, E. M.; Muschamp, J. W.; Sato, S. Dopamine and serotonin: influences on male sexual behavior Physiol. Behav. 2004, 83, 291-307
13. Millan, M. J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 2006, 110, 135-370
14. Liang, Y.; Richelson, E. Triple reuptake inhibitors: Next-generation antidepressants Prim. Psychiatry 2008, 15, 50-56
15. Prins, J.; Olivier, B.; Korte, S. M. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited Expert Opin. Invest. Drugs 2011, 20, 1107-1130
16. Ishichi, Y.; Kimura, E.; Honda, E.; Yoshikawa, M.; Nakahata, T.; Terao, Y.; Suzuki, A.; Kawai, T.; Arakawa, Y.; Ohta, H.; Kanzaki, N.; Nakagawa, H.; Terauchi, J. Novel triple reuptake inhibitors with low risk of CAD associated liabilities: Design, synthesis and biological activities of 4-[(1S)-1-(3,4-dichlorophenyl)-2-methoxyethyl]piperidine and related compounds Bioorg. Med. Chem. 2013, 21, 4600-4613
17. Shao, L.; Li, W.; Xie, Q.; Yin, H. Triple reuptake inhibitors: a patent review (2006-2012) Expert Opin. Ther. Pat. 2014, 24, 131-154
18. Han, Y.; Han, M.; Shin, D.; Song, C.; Hahn, H.-G. Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors J. Med. Chem. 2012, 55, 8188-8192
19. Lima, L. M.; Barreiro, E. J. Bioisosterism: A useful strategy for molecular modification and drug design Curr. Med. Chem. 2005, 12, 23-49
20. Patani, G. A.; LaVoie, E. J. Bioisosterism: A rational approach in drug design Chem. Rev. 1996, 96, 3147-3176
21. Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond Expert Opin. Invest. Drugs 2007, 16, 1365-1377
22. Jørgensen, S.; Nielsen, E. Ø.; Peters, D.; Dyhring, T. Validation of a fluorescence-based high-throughput assay for the measurement of neurotransmitter transporter uptake activity J. Neurosci. Methods 2008, 169, 168-176
23. It was known that most of the launched antidepressants are metabolized by CYP1A2 and that CYP2D6 and CYP3A4 are responsible for metabolism over 80% of drugs. Lynch, T.; Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects Am. Fam. Physician 2007, 76, 391-396
24. Zhou, P.-Z.; Babcock, J.; Liu, L.-Q.; Li, M.; Gao, Z.-B. Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules Acta Pharmacol. Sin. 2011, 32, 781-788
25. Raschi, E.; Vasina, V.; Poluzzi, E.; De Ponti, F. The hERG K+ channel: target and antitarget strategies in drug development Pharmacol. Res. 2008, 57, 181-195
26. Choi, K. H.; Song, C.; Shin, D.; Park, S. hERG channel blockade by externally applied quaternary ammonium derivatives Biochim. Biophys. Acta 2011, 1808, 1560-1566